# Laurus Labs share price today (Laurus Labs Ltd, NSE: LAURUSLABS)

> Laurus Labs share price today: ₹2,323.00 at the NSE close on 3 November 2026, up 143.6% in a year. Laurus Labs (NSE: LAURUSLABS) is worth ₹1,25,488 crore, trades at a P/E of 93.7 and has closed between ₹930.20 and ₹2,405.50 over the past 52 weeks. > Laurus Labs Ltd's earnings have grown faster than its share price. Earnings per share grew +147.9% in a year while the price moved +143.6%. LAURUSLABS · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/laurus-labs-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹2,323.00 (+143.6% in a year)
- P/E: 93.7× (higher than 84% of the last 9.9 years)
- Revenue (Sep 2026): ₹2,206 Cr (+33.5% on a year ago)
- Profit (Sep 2026): ₹436 Cr (+124.7% on a year ago)
- Operating margin: 34.0% (+10.0 points on a year ago)
- ROCE: 18%, FY26
- ROIC: 17.2%, against a 12.0% cost of capital: +5.2 points

The main question: results are strong, and the P/E is higher than 84% of its own history. ## What is the Laurus Labs share price today? Laurus Labs Ltd's share price was ₹2,323.00 at the close on 3 November 2026. It has been rising for 148 weeks. That is 49.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹930 and ₹2,406, and at that close it sat 94% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 46 weeks in a row. Over the last 9.9 years the share price moved +2,342% while the NIFTY 500 moved +220%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Laurus Labs this quarter? Three changes stood out: best operating margin in 16 quarters, revenue up on a year earlier for 8 quarters in a row and profit up on a year earlier for 8 quarters in a row. 1. Best operating margin in 16 quarters Operating margin was 34% in the September 2026 quarter, against 24% a year earlier. Why: The share of sales left as operating profit rose because more of the sales came from higher-margin products and the company ran its operations more efficiently. Next results: check whether the company keeps its gross margin above 60% and its EBITDA margin, a measure of operating profit, above 30%. From the earnings call on 29 Oct 2026. 2. Revenue up on a year earlier for 8 quarters in a row In the September 2026 quarter revenue was ₹2,206 crore, +33.5% on a year earlier. Why: Revenue rose because the company made much more medicine for other drug companies. Next results: check whether sales of medicine made for other drug companies hold up without customers running down their stock and the profit margin stays intact. From the earnings call on 29 Oct 2026. 3. Profit up on a year earlier for 8 quarters in a row In the September 2026 quarter profit was ₹436 crore, +124.7% on a year earlier. Why: Profit rose much faster than sales because more of the sales came from higher-margin products and the company ran its operations more efficiently. Next results: check whether gross margin stays above 60% and EBITDA margin, a measure of operating profit, stays above 30%. From the earnings call on 29 Oct 2026. ## What are Laurus Labs' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Laurus Labs reported revenue of ₹2,206 crore, up 33.5% from ₹1,653 crore a year earlier, and a profit of ₹436 crore, up 124.7% from ₹194 crore. ### Laurus Labs results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹2,206 crore | ₹1,653 crore | +33.5% |
| Profit | ₹436 crore | ₹194 crore | +124.7% |
| Earnings per share | ₹8.17 | ₹3.61 | +126.3% |
| Operating margin | 34.0% | 24.0% | +10.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Laurus Labs' management discussed these results on a call held on 29 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Laurus Labs share price history? Laurus Labs closed at ₹2,323.00 on 3 November 2026, up 143.6% from ₹953.65 a year earlier (31 October 2025) and up 366.0% over five years. Its highest weekly close since December 2016 was ₹2,405.50 on 30 October 2026. ### Laurus Labs share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,970.00 | +17.9% |
| 1 month ago · 1 Oct 2026 | ₹1,984.00 | +17.1% |
| 6 months ago · 30 Apr 2026 | ₹1,100.95 | +111.0% |
| 1 year ago · 31 Oct 2025 | ₹953.65 | +143.6% |
| 3 years ago · 3 Nov 2023 | ₹364.30 | +537.7% |
| 5 years ago · 4 Nov 2021 | ₹498.50 | +366.0% |
| 10 years ago · 23 Dec 2016 | ₹95.13 | +2,341.9% |
| Earliest weekly close in our records · 23 Dec 2016 | ₹95.13 | +2,341.9% |
| Highest weekly close since December 2016, also the 52-week high · 30 Oct 2026 | ₹2,405.50 | −3.4% |
| Lowest weekly close since December 2016 · 18 Oct 2019 | ₹63.24 | +3,573.3% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹930.20 | +149.7% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (523 weekly closes from 23 December 2016 to 3 November 2026.)

## What is the latest news on Laurus Labs? 6 Nov 2026: Coming up: ex-date for an interim dividend of ₹1 a share. 3 Nov 2026: Laurus Labs closed at ₹2,323.00, up 17.9% on the week and up 17.1% on the month. ### Earlier

- 29 Oct 2026: Laurus Labs held its results call for July to September 2026. Management guided: Gross margin above 60% and operating margin above 30% going forward. - Results for July to September 2026: Revenue up 33.5% and profit up 124.7% on a year earlier. - 8 May 2026: ex-date for an interim dividend of ₹1.20 a share. ## What dividend does Laurus Labs pay? Laurus Labs paid ₹1.20 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.05% at the ₹2,323.00 close on 3 November 2026. The last was an interim dividend of ₹1.20 a share, ex-date 8 May 2026. Next: ₹1 a share, ex-date 6 November 2026. ### Laurus Labs dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 6 Nov 2026 (upcoming) | ₹1 | Interim | same day |
| 8 May 2026 | ₹1.20 | Interim | same day |
| 31 Oct 2025 | ₹0.80 | Interim | same day |
| 9 May 2025 | ₹0.80 | Interim | same day |
| 6 Nov 2024 | ₹0.40 | Interim | same day |
| 8 May 2024 | ₹0.40 | Interim | same day |
| 2 Nov 2023 | ₹0.40 | Interim | same day |
| 10 May 2023 | ₹1.20 | Interim | same day |
| 3 Nov 2022 | ₹0.80 | Interim | 4 Nov 2022 |
| 10 May 2022 | ₹1.20 | Interim | 11 May 2022 |
| 17 Nov 2021 | ₹0.80 | Interim | 18 Nov 2021 |
| 11 May 2021 | ₹0.80 | Interim | 12 May 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Laurus Labs Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Laurus Labs management say on the latest results call? On the call for July to September 2026, held on 29 October 2026, Laurus Labs' management guided: Gross margin above 60% and operating margin above 30% going forward. > “Today, if any partner comes with a tech pack, we will not say no because we do not have the capabilities, except for monoclonal antibodies, cephalosporins, and penicillins. Those are the areas we do not have right now.”
> Dr Satyanarayana Chava, on the call for July to September 2026

### What management guided

- Peptide validation batches to begin in 12-18 months on commercial-scale block. - Peptide commercial revenues from current capacities around 2029 with high validation utilization. - LB-4 fermentation operational by end-2026 and KRKA JV Phase-1 blocks from mid-2027 with revenues in 2028-2029. - Capital spending ₹2,000 crore each in 2027 and 2028 then around ₹1,500 crore annually thereafter. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/19736-29-Oct-2026.pdf). (From the call for July to September 2026, 29 October 2026.)

## What to watch in Laurus Labs' next results? When Laurus Labs reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Peptide validation campaigns to commence on commercial block with high utilization - check start and scale per flagged window. - What to check (from the call)
- Peptide validation campaigns to commence on commercial block with high utilization - check start and scale per flagged window. - LB-4 facility to turn operational with trials and reserved volumes converting - check commissioning and uptake per flagged timeline. ## Which stock lists is Laurus Labs on? Laurus Labs is on 3 of our India lists: Momentum stocks, 52 week high & low and Pharma stocks. - [Momentum stocks Market cap cr: 126865.20723342341](https://www.sectoralpha.in/momentum-stocks-india)
- [52 week high & low 52-week position: At 52-week high](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Pharma stocks Market value (₹ crore): 126865.20723342341](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Laurus Labs profitable? Laurus Labs Ltd earned ₹436 Cr of net profit in the Sep 2026 quarter, +124.7% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹890 Cr. Over 10 years profit has grown 20.8% a year on average. That is 19.8% of the quarter's revenue. The same quarter a year earlier earned ₹194 Cr. For the full year, FY26 profit was ₹890 Cr (+148.6% on the year before). Why profit moved: revenue changed +33.5% on a year earlier and the margin moved +10.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +110.0% and revenue +23.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Laurus Labs make, and is it growing? Laurus Labs Ltd reported ₹2,206 Cr of revenue in the Sep 2026 quarter, +33.5% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 14.4% a year on average. The last full year, FY26, came in at ₹6,813 Cr. The last four reported quarters add to ₹7,822 Cr. FY26 revenue was ₹6,813 Cr, +22.7% on the year before. Recent pace: the last four quarters grew +23.4% on average, against 14.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +23.0%, against +24.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +95.3%, against +218.9% a year (rolling over). ## How much of every ₹100 of sales does Laurus Labs keep? Laurus Labs Ltd's operating margin was 34.0% in the Sep 2026 quarter, 10.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 15.0% and 32.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +9.6 percentage points on the year while gross margin changed +3.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Laurus Labs' profit turning into cash? Over the last 3 years, 205% of Laurus Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,624 Cr of operating cash against ₹890 Cr of profit. After ₹1,043 Cr of spending on assets, ₹581 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 205% of profit came in as cash: the cash cycle got 97 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building. ## Where does Laurus Labs' cash go? Laurus Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 166 days in FY21. It spent ₹2,479 Cr on assets over the last 3 years. Customers take 115 days to pay, and stock sits for 317 days on average. At FY26 sales of ₹6,813 Cr, each day of that cycle ties up about ₹18.7 Cr, so roughly ₹4,909 Cr is tied up in the business at any time. FY26: customers took 115 days to pay and stock sat for 317 days, about 10.4 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 166. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 317 days. Customers pay about 115 days after that. Suppliers are paid at 170 days. Together that makes the 263-day cycle. Spending on assets: ₹2,479 Cr over the last 3 years, against ₹1,295 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹773 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Laurus Labs' P/E ratio, and how does it compare with its own history? Laurus Labs Ltd's P/E is 93.7×, near the high end of its own history: higher than 84% of past readings. Its usual P/E (the middle reading) is 35.5×, over 9.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +147.9% while the price moved +143.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +36.0% a year; about +5.6% a year came from earnings growth and about +30.4 percentage points from the multiple (the market paying more); over 10 years the price moved +37.6% a year; about +25.6% a year came from earnings growth and about +12.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Laurus Labs business getting better or worse? Laurus Labs Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +318.4% at its peak to +95.3%, but the business is still expanding, with ROCE rising at 27.9%. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Laurus Labs earn on its capital? Laurus Labs Ltd earned a ROCE of 18% in FY26. That is up from a low of 7% in FY24. Its return on capital used (ROIC) is 5.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.1% net margin and 0.65× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.1% net margin × 0.65× asset turnover × 1.98× leverage (assets divided by equity) ≈ 16.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 17.2% − 12.0% = +5.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 17.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Laurus Labs have too much debt? Laurus Labs Ltd has total debt of ₹2,625 Cr against shareholder equity of ₹6,181 Cr as of Sep 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 0.53 in FY22 to 0.46 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Laurus Labs shareholding pattern? Foreign institutions raised their stake in Laurus Labs Ltd by 4.8 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 30.8% of the company. Domestic institutions moved −1.2 points over the same period, to 11.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +4.8 points over 8 quarters, to 30.8%; Domestic institutions: −1.2 points over 8 quarters, to 11.9%; Promoters: +0.3 points over 8 quarters, to 27.5%. Why the owners changed: foreign institutions drove it (+4.8 points), with the other side taken by domestic institutions (−1.2 points). They raised their stake step by step. ## How far is Laurus Labs from balance-sheet trouble? For Laurus Labs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Laurus Labs rank in its industry? 71.0 out of 100, rank 3 of 24 in Pharma - API & CRAMS, with 93% of the evidence available. Laurus Labs Ltd scores 71.0 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 3. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 30.9 + 17.3 + 5.8 + 17 = 71. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Laurus Labs compared with? Laurus Labs ranks 3 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 71.0 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. Laurus Labs Ltd this page LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Laurus Labs in size? Laurus Labs is the 2nd largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Divis Laboratories. Just below it: Gland Pharma, Anthem Biosciences, Sai Life Sciences, Acutaas Chemicals and Piramal Pharma. ### Pharma - API & CRAMS companies close in size

1. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) ₹2,59,628 crore
2. Laurus Labs Ltd ₹1,29,972 crore
3. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) ₹51,086 crore
4. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ₹46,689 crore
5. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) ₹33,093 crore
6. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ₹32,778 crore
7. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) ₹31,807 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [ICICI Prudential Asset Management Co Ltd](https://www.sectoralpha.in/stocks/icici-prudential-asset-management-co-ltd) ₹1,33,791 crore · Finance - AMC
2. [Varun Beverages Ltd](https://www.sectoralpha.in/stocks/varun-beverages-ltd) ₹1,32,594 crore · FMCG - Contract Mfg
3. Laurus Labs Ltd ₹1,29,972 crore
4. [Vodafone Idea Ltd](https://www.sectoralpha.in/stocks/vodafone-idea-ltd) ₹1,28,170 crore · Telecom Services
5. [CG Power & Industrial Solutions Ltd](https://www.sectoralpha.in/stocks/cg-power-industrial-solutions-ltd) ₹1,26,668 crore · Capital Goods - Transformers

## What else do people ask about Laurus Labs? ### What is Laurus Labs's share price today? Laurus Labs Ltd's share price is ₹2,323.00, +143.6% over the past year. The whole company is worth ₹1,25,488 Cr on the market. In the last 52 weeks it traded between ₹930 to ₹2,406; today it is 94% of the way up from the low, 49.6% above its 200-day average (as of 3 November 2026). ### What were Laurus Labs's latest quarterly results? Laurus Labs Ltd reported revenue of ₹2,206 Cr and net profit of ₹436 Cr for the Sep 2026 quarter. Revenue rose 33.5% and profit rose 124.7% compared with a year earlier. Earnings per share were ₹8.17. The operating margin was 34.0%, 10.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Laurus Labs's market cap? Laurus Labs Ltd's market capitalisation is ₹1,25,488 Cr at a share price of ₹2,323.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Laurus Labs performing? Laurus Labs Ltd's share price has been rising for 148 weeks. In its latest quarter, revenue rose 33.5% and profit rose 124.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 46 weeks running (as of 3 November 2026). ### Will Laurus Labs's share price go up? This page does not forecast Laurus Labs Ltd's share price. What it shows instead: the share price is ₹2,323.00, and it has been rising for 148 weeks. Its P/E of 93.7× is higher than 84% of its own last 10 years (as of 3 November 2026). ### Who owns Laurus Labs? Promoters own 27.5% of Laurus Labs Ltd, foreign institutions 30.8%, domestic institutions 11.9% and the public 29.9% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 4.8 percentage points over 8 quarters (as of 3 November 2026). ### Does Laurus Labs have too much debt? Laurus Labs Ltd has a moderate amount of debt: its debt is 0.48× its equity, and its operating profit is 10 times its interest bill. FY26 borrowings were ₹2,518 Cr against equity of ₹5,300 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Laurus Labs in its business cycle? Laurus Labs Ltd's FY26 operating margin was 26.0%, against a 13-year range of 15.0% to 32.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 34.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Laurus Labs story? The main question: results are strong, and the P/E is higher than 84% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Laurus Labs a stock worth studying right now? What the numbers show: Laurus Labs Ltd's earnings have grown faster than its share price. Earnings per share grew +147.9% in a year while the price moved +143.6%. The main open question: whether earnings grow enough to match the multiple. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Laurus Labs share price forecast for 2026? What management itself guided: Gross margin above 60% and operating margin above 30% going forward. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.